Barclays Maintains Overweight on Exelixis, Raises Price Target to $25

Exelixis, Inc. -4.31% Pre

Exelixis, Inc.

EXEL

44.16

44.16

-4.31%

0.00% Pre
Barclays analyst Peter Lawson maintains Exelixis (NASDAQ: EXEL) with a Overweight and raises the price target from $24 to $25.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via